Novel use of ginsenoside Rg1

A technology of ginsenosides and uses, which is applied in the field of new uses of ginsenoside Rg1, and can solve problems such as unreported

Inactive Publication Date: 2006-02-15
INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
View PDF0 Cites 11 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the use of ginsenoside Rg1 in the prevention and/or

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel use of ginsenoside Rg1
  • Novel use of ginsenoside Rg1

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Effect of embodiment 1Rg1 on mouse sexual behavior

[0022] Before the experiment, the mice were trained, selected, and grouped so that the sexual behavior experience and mating background of the mice in each group were basically the same. Rg1, 10, 5, and 25 mg / kg were injected intraperitoneally once every morning, and the female mice were placed in the male mice at night. In the cage, observe its sexual behavior that is straddle (mounting) and mating (mating) times, the result proves that about 2 weeks after administration of Rg1, the mouse's sexual behavior is obviously improved, the results are shown in Figure 1a with 1b .

Embodiment 2

[0023] The influence of embodiment 2 on the relaxing effect of cavernous body

[0024] Three mechanisms have been shown to be involved in the regulation of the tone of the postcavernosal spiral arteries, namely adrenergic, cholinergic and nonadrenergic, noncholinergic (NANC), the latter being considered the host mechanism for relaxation of cavernous vascular smooth muscle, NO is the nerve mediator of NANC. NO acts on guanylate cyclase (GC) to form a NO-GC complex, and combines with the porphyrin part of the enzyme, resulting in a change in configuration and activation of GC, thereby making the cell A large amount of cGMP is formed, which is the NO-cGMP pathway that is closely related to the erectile function of the genitals. Therefore, we observed the effects of Rg1 on the relaxation of the cavernous body, the accumulation of cGMP and the release of NO in the cavernous body.

[0025] We used methylcholine (MCH) as a tool drug for endogenous NO release to observe the effect of ...

Embodiment 3

[0044] PDB5 (type 5 PDE) in the cyclic nucleotide phosphodiesterase (PDE) family is closely related to the reproductive system. It is mainly distributed in the cavernous tissue and platelets of animals, with cGMP as the specific substrate, and GTP in the Under the action of GC, cGMP is formed, and cGMP is hydrolyzed into 5'GMP by PDEs, so the inhibition of PDEs can cause the accumulation of cGMP in the cavernous body, which in turn leads to dilation of the cavernous blood vessels and penile erection.

[0045] Ginsenosides provided by the Chinese Institute of Materia Medica, code-named: Sildenafil: produced by China Dalian Pfizer Pharmaceutical Co., Ltd., batch number 25883002; 125I The radioimmunoassay cGMp test kit is a product of Amersham Company, batch number 60440504; PDE is a genetic recombination engineering product of Mark Company; batch number: CA92039-2087; dimethyl sulfoxide (dimethylsmlphoxide, DMSO) Hongsheng Chemical Factory produces; batch number 950726. The inst...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a novel use of ginsenoside Rg1, especially the use in preventing or treating male sexual dysfunction such as ejection dysfunction.

Description

field of invention [0001] The present invention relates to the new use of ginsenoside Rg1, especially the use in preventing or treating male sexual dysfunction such as erectile dysfunction. Background technique [0002] Ginsenoside Rg1 is a known chemical monomer present in many plants such as ginseng. Its structure and relevant biological activities have been reported in relevant textbooks or published literature. However, the use of ginsenoside Rg1 in the prevention and / or treatment of male sexual function has not been reported so far. Contents of the invention [0003] The inventors now find that ginsenoside Rg1 inhibits phosphodiester ester V (PDE v ) to increase the concentration of CGMP, thereby promoting the erectile function of the cavernous body. [0004] Therefore, the first aspect of the present invention relates to the use of ginsenoside Rg1 in the preparation of products for preventing and / or treating sexual dysfunction. [0005] Another aspect of the pres...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/704A61P15/10
Inventor 张均田王晓英郝顺祖黄诒森
Owner INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap